Lenvatinib 4mg 1 Capsule [Prescription Required]
LENVIMA Lenvatinib 4mg 1 Capsule
For treatment of patients with unresectable thyroid cancer. In combination with everolimus, for the treatment of patients with advanced renal cell carcnoma (RCC) following one prior antiangiogenic theraphy. For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). In combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.
Place of Origin
THYROID CANCER The recommended daily dose of lenvatinib is 24 mg (two 10 mg capsules and one 4 mg capsule) taken once daily. RENAL CELL CARCINOMA The recommended dose of lenvatinib is 18 mg (one 10 mg capsule and two 4 mg capsules) in combination with 5 mg everolimus taken once daily. HEPATOCELLULAR CARCINOMA The recommended daily dose of lenvatinib is 8˜mg (two 4˜mg capsules) once daily for patients with a body weight of <˜60˜kg and 12˜mg (three 4˜mg capsules) once daily for patients with a body weight of •˜60˜kg. The daily dose is to be modified, as needed, according to the dose/toxicity management plan. Or as prescribed by the physician. ENDOMETRIAL CARCINOMA The recommended dosage of lenvatinib is 20 mg orally once daily in combination with pembrolizumab 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks until unacceptable toxicity or disease progression. Or as prescribed by the physician. Refer to the prescribing information for pembrolizumab for further recommended dosing information, as appropriate.